Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Myasthenic Syndromes, Congenital: later-stage trial registry
1 of 2 indexed Myasthenic Syndromes, Congenital trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Myasthenic Syndromes, Congenital: 2 US clinical trials tracked, 1 recruiting.
Myasthenic Syndromes, Congenital is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Catalyst Pharmaceuticals, running 1 of these trials.
Enrollment posture brief
Registry condition myasthenic-syndromes-congenital
OPEN 1 | RECR 50% | LATE 1 | EARLY 0 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Myasthenic Syndromes, Congenital lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Myasthenic Syndromes, Congenital on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Myasthenic Syndromes, Congenital is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
A Prospective Natural History and Outcome Measure Validation Study of Congenital Myasthenic Syndromes
National Institute of Neurological Disorders and Stroke (NINDS)
NCT06630650
Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes
Catalyst Pharmaceuticals
NCT02562066
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Myasthenic Syndromes, Congenital records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Myasthenic Syndromes, Congenital trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Myasthenic Syndromes, Congenital page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Myasthenic Syndromes, Congenital trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Catalyst Pharmaceuticals sponsors the most Myasthenic Syndromes, Congenital trials on record, review their full trial history before evaluating a specific study. See Catalyst Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Myasthenic Syndromes, Congenital condition card totals 2 registered trials; most-linked intervention amifampridine phosphate; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.